Professor Green

Dr. Professor Green


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2020 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
LBLouise Bowles
Louise Bowles
SPSean Platton
Sean Platton
NYNada Yartey
Nada Yartey
MDMinal Dave
Minal Dave
KLKurtis Lee
Kurtis Lee
PMPeter MacCallum
Peter MacCallum
Patients with coronavirus disease 2019 (Covid-19) have a profound hypercoagulable state, and complicating venous thrombotic events are common.1-3 Abnormalities in coagulation screening measures, including a prolonged activated partial-thromboplastin time (aPTT), have been reported in patients with Covid-19.4 This finding could be seen as a reason to avoid the use of anticoagulation at both therapeutic and prophylactic doses.

1 July 2015 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
NCNicola Curry
Nicola Curry
CRC. Rourke
C. Rourke
RDR. Davenport
R. Davenport
SBS. Beer
S. Beer
LPL. Pankhurst
L. Pankhurst
SSS. Stanworth
S. Stanworth
Low fibrinogen (Fg) concentrations in trauma haemorrhage are associated with poorer outcomes. Cryoprecipitate is the standard source for Fg administration in the UK and USA and is often given in the later stages of transfusion therapy. It is not known whether early cryoprecipitate therapy improves clinical outcomes. The primary aim of this feasibility study was to determine whether it was possible to administer cryoprecipitate, within 90 min of admission to hospital. Secondary aims were to evaluate laboratory measures of Fg and clinical outcomes including thrombotic events, organ failure, length of hospital stay and mortality. This was an unblinded RCT, conducted at two civilian UK major trauma centres of adult trauma patients (age ≥16 yrs), with active bleeding and requiring activation of the major haemorrhage protocol. Participants were randomised to standard major haemorrhage therapy (STANDARD) (n=22), or to standard haemorrhage therapy plus two early pools of cryoprecipitate (CRYO) (n=21). 85% (95% CI: 69-100%) CRYO participants received cryoprecipitate within 90 min, median time 60 min (IQR: 57-76) compared with 108 min (67-147), CRYO and STANDARD arms respectively (P=0.002). Fg concentrations were higher in the CRYO arm and were maintained above 1.8 g litre(-1) at all time-points during active haemorrhage. All-cause mortality at 28 days was not significantly different (P=0.14). Early Fg supplementation using cryoprecipitate is feasible in trauma patients. This study supports the need for a definitive RCT to determine the effect of early Fg supplementation on mortality and other clinical outcomes. ISRCTN55509212.

12 March 2018 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
Professor GreenProfessor Green
Professor Green
PBPaula Bolton‐Maggs
Paula Bolton‐Maggs
CBCraig Beattie
Craig Beattie
RCRebecca Cardigan
Rebecca Cardigan
YKYiannis Kallis
Yiannis Kallis
SZSharon Zahra
Sharon Zahra
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

1 March 2019 in Shock
Verified
Journal Article
Closed access
MRMarius Rehn
Marius Rehn
AWAnne Weaver
Anne Weaver
KBKarim Brohi
Karim Brohi
SESarah Eshelby
Sarah Eshelby
Professor GreenProfessor Green
Professor Green
DLDavid J. Lockey
David J. Lockey
Background: Current management principles of hemorrhagic shock after trauma emphasize earlier transfusion therapy to prevent dilution of clotting factors and correct coagulopathy. London's Air Ambulance (LAA) was the first UK civilian prehospital service to routinely offer prehospital red blood cell (RBC) transfusion (phRTx). We investigated the effect of phRTx on mortality. Methods: Retrospective trauma database study comparing mortality before implementation with after implementation of phRTx in exsanguinating trauma patients. Univariate logistic regression was performed for the unadjusted association between phRTx and mortality was performed, and multiple logistic regression adjusting for potential confounders. Results: We identified 623 subjects with suspected major hemorrhage. We excluded 84 (13.5%) patients due to missing data on survival status. Overall 187 (62.3%) patients died in the before phRTx period and 143 (59.8%) died in the after phRTx group. There was no significant improvement in overall survival after the introduction of phRTx (P = 0.554). Examination of prehospital mortality demonstrated 126 deaths in the pre-phRTx group (42.2%) and 66 deaths in the RBC administered group (27.6%). There was a significant reduction in prehospital mortality in the group who received RBC (P < 0.001). Conclusions: phRTx was associated with increased survival to hospital, but not overall survival. The “delay death” effect of phRTx carries an impetus to further develop inhospital strategies to improve survival in severely bleeding patients.

23 December 2015 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
Professor GreenProfessor Green
Professor Green
MKM Knight
M Knight
FSFm Seeney
Fm Seeney
CHC Hopkinson
C Hopkinson
PCPw Collins
Pw Collins
SSSs Stanworth
Ss Stanworth
Objective: To ascertain the incidence of massive transfusion (MT) in obstetrics in the UK, and describe its management and clinical outcomes.Design: A population‐based cross‐sectional study conducted through the UK Obstetric Surveillance System (UKOSS).Settings: All UK hospitals with consultant‐led maternity units.Population: Any pregnant woman at ≥20 weeks of gestation receiving ≥8 units of red blood cells within 24 hours of giving birth, from July 2012 to June 2013.Methods: Prospective case identification through the monthly mailing of UKOSS.Results: We identified 181 women who had undergone MT, making the estimated incidence of MT associated with postpartum haemorrhage (PPH) 23 per 100 000 maternities (95% confidence interval 19–26) per year. The median estimated blood loss was 6 l (interquartile range 4.5–8.0 l). The majority of women presented outside working hours (63%), 40% had had previous caesarean sections and 3% had normal vaginal births without risk factors. The main cause for MT was uterine atony (40%) and the main mode of birth was caesarean section (69%). Of the 181 women, 15 received >20 units of red blood cells. In total, 45% of women underwent hysterectomy, and among all causes of PPH, placenta accreta had the highest hysterectomy rate. Two women died, 82% were admitted to intensive care/high‐dependency units, and 28% developed major morbidities.Conclusion: Massive transfusion due to PPH is associated with high rates of morbidity and hysterectomy. Clinical and research efforts should focus on approaches to recognise and optimise timely resuscitation and management of these severe cases.Tweetable Massive transfusion due to postpartum haemorrhage is associated with high rates of morbidity and hysterectomy.

10 June 2022 in British Journal of Haematology
Verified
Journal Article
Closed access
SSSimon J. Stanworth
Simon J. Stanworth
KDKerry Dowling
Kerry Dowling
NCNikki Curry
Nikki Curry
HDHeidi Doughty
Heidi Doughty
BHBeverley Jane Hunt
Beverley Jane Hunt
THThe Transfusion Task Force Of The British Society For Haematology
The Transfusion Task Force Of The British Society For Haematology